• New PD-1 cancer vaccine named KEY-Vaxx
• Phase 1 planning well advanced
• Preclinical results in validated models of colorectal (colon) cancer
demonstrate inhibitory cancer growth activity
MELBOURNE Australia 23 July 2018: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company is pleased to announce a development update of its newly acquired PD-1 cancer vaccine from Ohio State University. The check-point inhibitor cancer vaccine named KEY-Vaxx, demonstrates superior cancer growth inhibition compared with an industry-standard monoclonal antibody in validated models of colorectal (colon) cancer (CT26).
For further information please download PDF attached:
Download this document
